Floatz logo

Nivolumab

Breast Secretory Carcinoma

Explore 1 assets in Breast Secretory Carcinoma →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Instituto do Cancer do Estado de São Paulo
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Breast Secretory Carcinoma

AssetSponsorPhaseRating
Nivolumab (this asset)Instituto do Cancer do Estado de São PauloP2CCC · 53

Other indications for Nivolumab

IndicationSponsorPhaseRating
Renal Carcinoma—P4BBB · 72
Metastatic Melanoma—P4BB · 70
Non-Small Cell Lung Carcinoma—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Nivolumab in Breast Secretory Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nivolumab-breast-secretory-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →